High Resolution Crystal Structure of the Pyruvate Kinase Tetramer in Complex with the Allosteric Activator Mitapivat/AG-348

被引:0
|
作者
Han, Xiao [1 ,2 ]
Sandalova, Tatyana [1 ,2 ]
Zhang, Cheng [3 ]
Mardinoglu, Adil [3 ,4 ]
Achour, Adnane [1 ,2 ]
Sun, Renhua [1 ,2 ]
机构
[1] Karolinska Univ Hosp, Dept Med Solna, Karolinska Inst, Sci Life Lab, S-17165 Stockholm, Sweden
[2] Karolinska Univ Hosp, Div Infect Dis, S-17165 Stockholm, Sweden
[3] KTH Royal Inst Technol, Dept Prot Sci, Sci Life Lab, S-17121 Stockholm, Sweden
[4] Kings Coll London, Fac Dent Oral & Craniofacial Sci, Ctr Host & Microbiome Interact, London SE1 9RT, England
关键词
human pyruvate kinase; PK deficiency; Mitapivat; crystal structure; DEFICIENCY; SITE; M2;
D O I
10.3390/cryst14050441
中图分类号
O7 [晶体学];
学科分类号
0702 ; 070205 ; 0703 ; 080501 ;
摘要
Pyruvate kinase (PK) deficiency is a rare genetic disorder that affects this critical enzyme within the glycolysis pathway. In recent years, Mitapivat (MTPV, AG-348) has emerged as a notable allosteric activator for treating PK deficiency. However, the allosteric regulatory effects exerted on PK by MTPV are yet to be comprehensively elucidated. To shed light on the molecular mechanisms of the allosteric effects, we employed crystallography and biophysical methods. Our efforts yielded a high-resolution crystal structure of the PK tetramer complexed with MTPV at 2.1 & Aring; resolution. Isothermal titration calorimetry measurements revealed that MTPV binds to human PK with an affinity of 1 mu M. The enhanced structural details now allow for unambiguous analysis of the MTPV-filled cavity intricately embedded within the enzyme. Finally, the structure suggests that MTPV binding induces an allosteric effect on the B-domain situated proximal to the active site. In summary, our study provides valuable insights into the allosteric regulation of PK by MTPV and paves the way for further structure-based drug optimization for therapeutic interventions in PK deficiency.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Decreased Activity and Stability of Pyruvate Kinase in Hereditary Hemolytic Anemia: A Potential Target for Therapy By AG-348 (Mitapivat), an Allosteric Activator of Red Blood Cell Pyruvate Kinase
    Rab, Minke A. E.
    van Oirschot, Brigitte A.
    van Straaten, Stephanie
    Biemond, Bart J.
    Bos, Jennifer
    Kosinski, Penelope A.
    Kung, Charles
    van Beers, Eduard J.
    van Wijk, Richard
    BLOOD, 2019, 134
  • [2] A phase 1 dose escalation study of the pyruvate kinase activator mitapivat (AG-348) in sickle cell disease
    Xu, Julia Z.
    Conrey, Anna
    Frey, Ingrid
    Gwaabe, Eveline
    Menapace, Laurel A.
    Tumburu, Laxminath
    Lundt, Maureen
    Lequang, Timothy
    Li, Quan
    Glass, Kristen
    Dunkelberger, Emily B.
    Iyer, Varsha
    Mangus, Heidi
    Kung, Charles
    Dang, Lenny
    Kosinski, Penelope A.
    Hawkins, Peter
    Jeffries, Neal
    Eaton, William A.
    Thein, Swee Lay
    BLOOD, 2022, 140 (19) : 2053 - 2062
  • [3] Long-Term Safety and Efficacy of Mitapivat (AG-348), a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency: The DRIVE PK Study
    Grace, Rachael F.
    Layton, D. Mark
    Galacteros, Frederic
    Barcellini, Wilma
    van Beers, Eduard J.
    Yaish, Hassan M.
    Ravindranath, Yaddanapudi
    Kuo, Kevin H. M.
    Sheth, Sujit
    Kwiatkowski, Janet L.
    Hua, Lei
    Hawkins, Peter F.
    Mix, Chris
    Glader, Bertil
    BLOOD, 2019, 134
  • [4] Characterization of Metabolic Response to AG-348, an Allosteric Activator of Red Cell Pyruvate Kinase, in Healthy Volunteers and Pyruvate Kinase Deficiency Patients
    Chubukov, Victor
    Johnson, Kendall
    Kosinski, Penelope A.
    Clasquin, Michelle
    Jha, Abhishek
    Kim, Hyeryun
    Roddy, Thomas P.
    Merica, Elizabeth
    Barbier, Ann J.
    Dang, Lenny
    Silverman, Lee
    Kung, Charles
    BLOOD, 2016, 128 (22)
  • [5] AG-348 (mitapivat), an allosteric activator of red blood cell pyruvate kinase, increases enzymatic activity, protein stability, and adenosine triphosphate levels over a broad range of PKLR genotypes
    Rab, Minke A. E.
    van Oirschot, Brigitte A.
    Kosinski, Penelope A.
    Hixon, Jeffrey
    Johnson, Kendall
    Chubukov, Victor
    Dang, Lenny
    Pasterkamp, Gerard
    van Straaten, Stephanie
    van Solinge, Wouter W.
    van Beers, Eduard J.
    Kung, Charles
    van Wijk, Richard
    HAEMATOLOGICA, 2021, 106 (01) : 238 - 249
  • [6] Results Update from the DRIVE PK Study: Effects of AG-348, a Pyruvate Kinase Activator, in Patients with Pyruvate Kinase Deficiency
    Grace, Rachael F.
    Layton, D. Mark
    Galacteros, Frederic
    Rose, Christian
    Barcellini, Wilma
    Morton, D. Holmes
    Van Beers, Eduard J.
    Yaish, Hassan M.
    Ravindranath, Yaddanapudi
    Kuo, Kevin H. M.
    Sheth, Sujit
    Kwiatkowski, Janet L.
    Silver, Bruce
    Kung, Charles
    Cohen, Marvin
    Yang, Hua
    Kosinski, Penelope A.
    Hua, Lei
    Barbier, Ann
    Glader, Bertil
    BLOOD, 2017, 130
  • [7] EFFECTS OF AG-348, A PYRUVATE KINASE ACTIVATOR, IN PATIENTS WITH PYRUVATE KINASE DEFICIENCY: UPDATED RESULTS FROM THE DRIVE PK STUDY
    Grace, R. F.
    Layton, D. M.
    Galacteros, F.
    Rose, C.
    Barcellini, W.
    Morton, D. H.
    van Beers, E.
    Yaish, H.
    Ravindranath, Y.
    Kuo, K.
    Sheth, S.
    Kwiatkowski, J. L.
    Silver, B.
    Kung, C.
    Cohen, M.
    Yang, H.
    Kosinski, P. A.
    Hua, L.
    Barbier, A.
    Glader, B.
    HAEMATOLOGICA, 2017, 102 : 164 - 164
  • [8] PRECLINICAL PHARMACOKINETIC/PHARMACODYNAMIC RELATIONSHIPS FOR AG-348, AN INVESTIGATIONAL SMALL-MOLECULE ACTIVATOR OF PYRUVATE KINASE
    Chen, Y.
    Kosinski, P.
    Histen, G.
    Kung, C.
    Kim, H.
    Dang, L.
    Popovici-Muller, J.
    Hixon, J.
    Silverman, L.
    Biller, S.
    Yang, H.
    HAEMATOLOGICA, 2015, 100 : 298 - 299
  • [9] Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study
    Grace, Rachael F.
    Rose, Christian
    Layton, D. Mark
    Yaish, Hassan M.
    Barcellini, Wilma
    Galacteros, Frederic
    Morton, D. Holmes
    Ravindranath, Yaddanapudi
    Kuo, Kevin H. M.
    van Beers, Eduard J.
    Kwiatkowski, Janet L.
    Silver, Bruce A.
    Merica, Elizabeth
    Kung, Charles
    Cohen, Marvin
    Yang, Hua
    Hixon, Jeffrey
    Kosinski, Penelope A.
    Silverman, Lee
    Dang, Lenny
    Yuan, Zheng
    Barbier, Ann J.
    Glader, Bertil
    BLOOD, 2016, 128 (22)
  • [10] Safety and Efficacy of Mitapivat (AG-348), an Oral Activator of Pyruvate Kinase R, in Subjects with Sickle Cell Disease: A Phase 2, Open-Label Study (ESTIMATE)
    Van Dijk, Lmyrthe J.
    Rab, Minke A. E.
    Rijneveld, Anita W.
    Nur, Erfan
    Bartels, Marije
    Jans, Judith J. M.
    van Sollinge, Wouter W.
    Schutgens, Roger E. G.
    van Wijk, Richard
    Van Beers, Eduard J.
    BLOOD, 2021, 138